Clarity Receives $10 million R&D Tax Incentive Refund
Sydney, Australia 24 June 2024 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that it has received a $9,951,692 Research and Development (R&D) Tax Incentive refund as part of the…